Abstract
Cardiac activator protein-1 (AP-1), composed of c-Jun, is significantly activated by hypertension or angiotensin II (AngII). This study was undertaken to elucidate whether c-Jun could be the potential target for treatment of cardiac hypertrophy. We constructed recombinant adenovirus carrying dominant-negative mutant of c-Jun (Ad.DN-c-Jun). Using catheter-based technique of adenoviral gene transfer, we achieved global myocardial transduction of DN-c-Jun in rats, to specifically inhibit cardiac AP-1. (1) AngII (200 ng/kg/min) infusion in rats caused cardiac hypertrophy, increased cardiac p70S6 kinase activity by 1.3-fold (P<0.05) and enhanced the gene expression of cardiac hypertrophic markers. Ad.DN-c-Jun, which was transferred to the heart 2 days before AngII infusion, prevented cardiac hypertrophy (P<0.01), decreased p70S6 kinase phosphorylation (P<0.05), and suppressed cardiac gene expression of brain natriuretic peptide, collagen I, III, and IV, monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) (P<0.01). (2) In genetically hypertensive rats with cardiac hypertrophy, cardiac gene transfer of Ad.DN-c-Jun, without affecting hypertension, regressed cardiac hypertrophy (P<0.05), and suppressed p70S6 kinase phosphorylation by 20% (P<0.05) and suppressed the enhanced expression of collagen I, III, and IV, MCP-1 and PAI-1. These results provided the first evidence that in vivo blockade of cardiac c-Jun inhibits pathologic cardiac hypertrophy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Leppa S, Bohmann D . Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 1999; 18: 6158–6162.
Yasumoto H, Kim S, Zhan Y, Miyazaki H, Hoshiga M, Kaneda Y et al. Dominant negative c-jun gene transfer inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in rats. Gene Therapy 2001; 8: 1682–1689.
Zhan Y, Kim S, Yasumoto H, Namba M, Miyazaki H, Iwao H . Effects of dominant-negative c-Jun on platelet-derived growth factor-induced vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol 2002; 22: 82–88.
Yano M, Kim S, Izumi Y, Yamanaka S, Iwao H . Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ Res 1998; 83: 752–760.
Izumi Y, Kim S, Murakami T, Yamanaka S, Iwao H . Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats. Hypertension 1998; 31: 50–56.
Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H . Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 1995; 25: 1252–1259.
Brown PH, Chen TK, Birrer MJ . Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene 1994; 9: 791–799.
Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996; 93: 1320–1324.
Xu ZL, Mizuguchi H, Mayumi T, Hayakawa T . Regulated gene expression from adenovirus vectors: a systematic comparison of various inducible systems. Gene 2003; 309: 145–151.
Hajjar RJ, Schmidt U, Matsui T, Guerrero JL, Lee KH, Gwathmey JK et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 1998; 95: 5251–5256.
Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K et al. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 1995; 273: 509–515.
Suto R, Tominaga K, Mizuguchi H, Sasaki E, Higuchi K, Kim S et al. Dominant-negative mutant of c-Jun gene transfer: a novel therapeutic strategy for colorectal cancer. Gene Therapy 2004; 11: 187–193.
Omura T, Yoshiyama M, Yoshida K, Nakamura Y, Kim S, Iwao H et al. Dominant negative mutant of c-Jun inhibits cardiomyocyte hypertrophy induced by endothelin 1 and phenylephrine. Hypertension 2002; 39: 81–86.
Kim S, Iwao H . Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11–34.
Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H . Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br J Pharmacol 1996; 118: 549–556.
Schmelzle T, Hall MN . TOR, a central controller of cell growth. Cell 2000; 103: 253–262.
Boluyt MO, Zheng JS, Younes A, Long X, O'Neill L, Silverman H et al. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. Circ Res 1997; 81: 176–186.
Sadoshima J, Izumo S . Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ Res 1995; 77: 1040–1052.
Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 2003; 107: 1664–1670.
Kim S, Zhan Y, Izumi Y, Iwao H . Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. Hypertension 2000; 35: 769–774.
Izumi Y, Kim S, Zhan Y, Namba M, Yasumoto H, Iwao H . Important role of angiotensin II-mediated c-Jun NH(2)-terminal kinase activation in cardiac hypertrophy in hypertensive rats. Hypertension 2000; 36: 511–516.
Nadal-Ginard B, Mahdavi V . Molecular basis of cardiac performance. Plasticity of the myocardium generated through protein isoform switches. J Clin Invest 1989; 84: 1693–1700.
Parker TG, Schneider MD . Growth factors, proto-oncogenes, and plasticity of the cardiac phenotype. Annu Rev Physiol 1991; 53: 179–200.
Acknowledgements
This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture (14370036 and 14570083), and Hoh-ansha Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim-Mitsuyama, S., Izumi, Y., Izumiya, Y. et al. Dominant-negative c-Jun inhibits rat cardiac hypertrophy induced by angiotensin II and hypertension. Gene Ther 13, 348–355 (2006). https://doi.org/10.1038/sj.gt.3302670
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302670
Keywords
This article is cited by
-
The role of c-Jun for beating cardiomycyte formation in prepared embryonic body
Stem Cell Research & Therapy (2023)
-
Multiscale model of heart growth during pregnancy: integrating mechanical and hormonal signaling
Biomechanics and Modeling in Mechanobiology (2022)
-
ACE-Triggered Hypertension Incites Stroke: Genetic, Molecular, and Therapeutic Aspects
NeuroMolecular Medicine (2020)
-
Macrophage-derived exosomes induce inflammatory factors in endothelial cells under hypertensive conditions
Hypertension Research (2017)
-
The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice
Hypertension Research (2012)